Department of Hepatobiliary Surgery and You-An Liver Transplant Center, Beijing You-An Hospital, Capital Medical University, Beijing, China.
J Surg Res. 2013 Aug;183(2):936-43. doi: 10.1016/j.jss.2013.03.008. Epub 2013 Mar 26.
Acute-on-chronic liver failure (ACLF) is a severe clinical condition for which liver transplantation (LT) is the only curative option. However, there are little published data on risk factors and outcomes of LT for ACLF.
The objective of this study was to analyze preoperative, intraoperative, postoperative, and overall survival data on 100 consecutive cases with ACLF in order to try to determine for which patients LT are futile.
One hundred consecutive patients with pathology-confirmed ACLF who underwent LT from June 2004 to September 2012 were enrolled. The preoperative data showed that all patients were in a serious condition with a median high model for end-stage liver disease (MELD) score of 32, total bilirubin of 440.20 umol/L, international normalized ratio (INR) of 3.012, and at least one organ dysfunction as assessed by a Sequential Organ Failure Assessment (SOFA) score of ≥9. The patients had either deceased or a living donor LT with an overall mortality of 20%. The 1-, 3-, and 5-year cumulative survival rates were 76.8%, 75.6%, and 74.1%, respectively, and graft 1-, 3-, and 5-y accumulative survival rates were 73.3%, 72.1%, and 70.6%, respectively. However, the area under receiver operating characteristic of SOFA score, MELD score, as well as Child-Pugh score were 0.552, 0.547, and 0.547, respectively.
Both deceased and living donor LT are effective therapeutic options for patients with ACLF and the short- and long-term survival rates are encouraging. It is important to conduct more prospective and multi-center studies to define preoperatively which patients would benefit from LT.
急性肝衰竭(ACLF)是一种严重的临床病症,肝移植(LT)是唯一的治疗选择。然而,关于 ACLF 的 LT 的风险因素和结果的数据很少。
本研究的目的是分析 100 例经病理学证实的 ACLF 患者的术前、术中、术后和总体生存数据,以确定哪些患者的 LT 是无效的。
2004 年 6 月至 2012 年 9 月,连续纳入 100 例经 LT 治疗的 ACLF 患者。术前数据显示,所有患者均处于严重状态,中位终末期肝病模型评分(MELD)为 32 分,总胆红素为 440.20 μmol/L,国际标准化比值(INR)为 3.012,至少有一个器官功能障碍,根据序贯器官衰竭评估(SOFA)评分≥9 分。患者接受了尸体或活体供者 LT,总体死亡率为 20%。1、3 和 5 年的累积生存率分别为 76.8%、75.6%和 74.1%,移植物的 1、3 和 5 年累积生存率分别为 73.3%、72.1%和 70.6%。然而,SOFA 评分、MELD 评分和 Child-Pugh 评分的受试者工作特征曲线下面积分别为 0.552、0.547 和 0.547。
尸体和活体供者 LT 都是 ACLF 患者的有效治疗选择,短期和长期生存率令人鼓舞。重要的是要进行更多的前瞻性和多中心研究,以确定术前哪些患者将受益于 LT。